All posts by admin

07May/14

Oxford BioTherapeutics Wins Rights to Amgen Antibodies, ImmunoGen ADC … – Genetic Engineering News

Oxford BioTherapeutics Wins Rights to Amgen Antibodies, ImmunoGen ADC
Genetic Engineering News
Oxford BioTherapeutics said today it obtained exclusive global rights to some of Amgen’s Xenomouse® antibodies and ImmunoGen’s maytansinoid antibody-drug conjugate (ADC) technology, with plans to develop a new ADC targeting an undisclosed …
Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse MarketWatch

all 4 news articles »